4E-BP1, a multifactor regulated multifunctional protein

References

• Wang XW, Zhang YJ. Targeting mTOR network in colorectal cancer therapy. World J Gastroenterol 2014; 20:4178-88; PMID:24764656; http://dx.doi.org/10.3748/wjg.v20.i15.4178
   PubMed Web of Science ®Google Scholar
• Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10:307-18; PMID:19339977; http://dx.doi.org/10.1038/nrm2672
   PubMed Web of Science ®Google Scholar
• Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 2010; 285:14071-7; PMID:20231296; http://dx.doi.org/10.1074/jbc.R109.094003
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274-93; PMID:22500797; http://dx.doi.org/10.1016/j.cell.2012.03.017
   PubMed Web of Science ®Google Scholar
• Lv T, Wang Q, Cromie M, Liu H, Tang S, Song Y, Gao W. Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer. Oncotarget 2015; 6:33006-18; PMID:26360779; http://dx.doi.org/10.18632/oncotarget.3400
   PubMed Web of Science ®Google Scholar
• Shull AY, Noonepalle SK, Awan FT, Liu J, Pei L, Bollag RJ, Salman H, Ding Z, Shi H. RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia. Oncotarget 2015; 6:14632-45; PMID:25999352; http://dx.doi.org/10.18632/oncotarget.4104
   PubMed Web of Science ®Google Scholar
• Martineau Y, Azar R, Bousquet C, Pyronnet S. Anti-oncogenic potential of the eIF4E-binding proteins. Oncogene 2013; 32:671-7; PMID:22508483; http://dx.doi.org/10.1038/onc.2012.116
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, Sonenberg N. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001; 15:2852-64; PMID:11691836; http://dx.doi.org/10.1101/gad.887201
   PubMed Web of Science ®Google Scholar
• Wang X, Li W, Parra JL, Beugnet A, Proud CG. The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation. Mol Cell Biol 2003; 23:1546-57; PMID:12588975; http://dx.doi.org/10.1128/MCB.23.5.1546-1557.2003
   PubMed Web of Science ®Google Scholar
• Heesom KJ, Denton RM. Dissociation of the eukaryotic initiation factor-4E/4E-BP1 complex involves phosphorylation of 4E-BP1 by an mTOR-associated kinase. FEBS Lett 1999; 457:489-93; PMID:10471835; http://dx.doi.org/10.1016/S0014-5793(99)01094-7
   PubMed Web of Science ®Google Scholar
• Sikalidis AK, Mazor KM, Kang M, Liu H, Stipanuk MH. Total 4EBP1 Is Elevated in Liver of Rats in Response to Low Sulfur Amino Acid Intake. J Amino Acids 2013; 2013:864757; PMID:24089634; http://dx.doi.org/10.1155/2013/864757
   PubMedGoogle Scholar
• Zhang Y, Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle (Georgetown, Tex) 2012; 11:594-603
   PubMed Web of Science ®Google Scholar
• Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008; 105:17414-9; PMID:18955708; http://dx.doi.org/10.1073/pnas.0809136105
   PubMed Web of Science ®Google Scholar
• Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, et al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 2014; 33:1590-600; PMID:23542178; http://dx.doi.org/10.1038/onc.2013.92
   PubMed Web of Science ®Google Scholar
• Mi W, Ye Q, Liu S, She QB. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis. Oncotarget 2015; 6:13962-77; PMID:25961827; http://dx.doi.org/10.18632/oncotarget.3920
   PubMed Web of Science ®Google Scholar
• Kang SA, Pacold ME, Cervantes CL, Lim D, Lou HJ, Ottina K, Gray NS, Turk BE, Yaffe MB, Sabatini DM. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 2013; 341:1236566; PMID:23888043; http://dx.doi.org/10.1126/science.1236566
   PubMed Web of Science ®Google Scholar
• She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB, Rosen N. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010; 18:39-51; PMID:20609351; http://dx.doi.org/10.1016/j.ccr.2010.05.023
   PubMed Web of Science ®Google Scholar
• Yoon SO, Roux PP. Rapamycin resistance: mTORC1 substrates hold some of the answers. Curr Biol 2013; 23:R880-3; PMID:24112984; http://dx.doi.org/10.1016/j.cub.2013.08.030
   PubMed Web of Science ®Google Scholar
• Shin S, Wolgamott L, Tcherkezian J, Vallabhapurapu S, Yu Y, Roux PP, Yoon SO. Glycogen synthase kinase-3beta positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1. Oncogene 2014; 33:1690-9; PMID:23584478; http://dx.doi.org/10.1038/onc.2013.113
   PubMed Web of Science ®Google Scholar
• Walsh D, Mohr I. Phosphorylation of eIF4E by Mnk-1 enhances HSV-1 translation and replication in quiescent cells. Genes Dev 2004; 18:660-72; PMID:15075293; http://dx.doi.org/10.1101/gad.1185304
   PubMed Web of Science ®Google Scholar
• Janzen C, Sen S, Cuevas J, Reddy ST, Chaudhuri G. Protein phosphatase 2A promotes endothelial survival via stabilization of translational inhibitor 4E-BP1 following exposure to tumor necrosis factor-α. Arteriosclerosis Thrombosis Vascular Biol 2011; 31:2586-94; PMID:21903942; http://dx.doi.org/10.1161/ATVBAHA.111.230946
   PubMed Web of Science ®Google Scholar
• Liu G, Zhang Y, Bode AM, Ma WY, Dong Z. Phosphorylation of 4E-BP1 is mediated by the p38/MSK1 pathway in response to UVB irradiation. J Biol Chem 2002; 277:8810-6; PMID:11777913; http://dx.doi.org/10.1074/jbc.M110477200
   PubMed Web of Science ®Google Scholar
• Haystead TA, Haystead CM, Hu C, Lin TA, Lawrence JC, Jr. Phosphorylation of PHAS-I by mitogen-activated protein (MAP) kinase. Identification of a site phosphorylated by MAP kinase in vitro and in response to insulin in rat adipocytes. J Biol Chem 1994; 269:23185-91; PMID:8083223
   PubMed Web of Science ®Google Scholar
• Braunstein S, Badura ML, Xi Q, Formenti SC, Schneider RJ. Regulation of protein synthesis by ionizing radiation. Mol Cell Biol 2009; 29:5645-56; PMID:19704005; http://dx.doi.org/10.1128/MCB.00711-09
   PubMed Web of Science ®Google Scholar
• Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009; 114:1618-27; PMID:19458359; http://dx.doi.org/10.1182/blood-2008-10-184515
   PubMed Web of Science ®Google Scholar
• Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003; 17:1841-54; PMID:12869584; http://dx.doi.org/10.1101/gad.1105003
   PubMed Web of Science ®Google Scholar
• Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 2005; 3:443-51; PMID:16123140; http://dx.doi.org/10.1158/1541-7786.MCR-05-0007
   PubMed Web of Science ®Google Scholar
• Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K, Miki H, Nakamura S, Harada T, Fujii S, et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 2011; 25:1182-8; PMID:21475253; http://dx.doi.org/10.1038/leu.2011.60
   PubMed Web of Science ®Google Scholar
• Yang DQ, Kastan MB. Participation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat Cell Biol 2000; 2:893-8; PMID:11146653; http://dx.doi.org/10.1038/35046542
   PubMed Web of Science ®Google Scholar
• Heesom KJ, Gampel A, Mellor H, Denton RM. Cell cycle-dependent phosphorylation of the translational repressor eIF-4E binding protein-1 (4E-BP1). Curr Biol 2001; 11:1374-9; PMID:11553333; http://dx.doi.org/10.1016/S0960-9822(01)00422-5
   PubMed Web of Science ®Google Scholar
• Greenberg VL, Zimmer SG. Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism. Oncogene 2005; 24:4851-60; PMID:15897904; http://dx.doi.org/10.1038/sj.onc.1208624
   PubMed Web of Science ®Google Scholar
• Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 2008; 27:2432-43; PMID:18701920; http://dx.doi.org/10.1038/emboj.2008.163
   PubMed Web of Science ®Google Scholar
• Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011; 11:23-34; PMID:21150935; http://dx.doi.org/10.1038/nrc2986
   PubMed Web of Science ®Google Scholar
• Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA, Nagle RB. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006; 66:1203-12; PMID:16652388; http://dx.doi.org/10.1002/pros.20410
   PubMed Web of Science ®Google Scholar
• Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, Cangiarella J, Arju R, Formenti SC, Schneider RJ. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 2007; 28:501-12; PMID:17996713; http://dx.doi.org/10.1016/j.molcel.2007.10.019
   PubMed Web of Science ®Google Scholar
• Karlsson E, Perez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, Sgroi DC, Nordenskjöld B, Hallbeck AL, Stål O. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res 2013; 15:R96; PMID:24131622; http://dx.doi.org/10.1186/bcr3557
   PubMed Web of Science ®Google Scholar
• Nathan CO, Amirghahari N, Abreo F, Rong X, Caldito G, Jones ML, Zhou H, Smith M, Kimberly D, Glass J. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2004; 10:5820-7; PMID:15355912; http://dx.doi.org/10.1158/1078-0432.CCR-03-0483
   PubMed Web of Science ®Google Scholar
• Martin ME, Perez MI, Redondo C, Alvarez MI, Salinas M, Fando JL. 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int J Biochem Cell Biol 2000; 32:633-42; PMID:10785360; http://dx.doi.org/10.1016/S1357-2725(00)00007-8
   PubMed Web of Science ®Google Scholar
• Chao MW, Wang LT, Lai CY, Yang XM, Cheng YW, Lee KH, Pan SL, Teng CM. eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer. Oncotarget 2015; 6:24092-104; PMID:26204490; http://dx.doi.org/10.18632/oncotarget.4483
   PubMed Web of Science ®Google Scholar
• Karlsson E, Waltersson MA, Bostner J, Perez-Tenorio G, Olsson B, Hallbeck AL, Stål O. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes Chromosomes Cancer 2011; 50:775-87; http://dx.doi.org/10.1002/gcc.20900
   PubMed Web of Science ®Google Scholar
• Ray ME, Yang ZQ, Albertson D, Kleer CG, Washburn JG, Macoska JA, Ethier SP. Genomic and expression analysis of the 8p11-12 Alicon in human breast cancer cell lines. Cancer Res 2004; 64:40-7; PMID:14729606; http://dx.doi.org/10.1158/0008-5472.CAN-03-1022
   PubMed Web of Science ®Google Scholar
• Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res 2009; 69:7803-10; PMID:19773438; http://dx.doi.org/10.1158/0008-5472.CAN-09-0910
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Ishihara H, Yamada T, Tamura A, Usui M, Tominaga R, Munakata Y, Satake C, Katagiri H, Tashiro F, et al. ATF4-mediated induction of 4E-BP1 contributes to pancreatic β cell survival under endoplasmic reticulum stress. Cell Metab 2008; 7:269-76; PMID:18316032; http://dx.doi.org/10.1016/j.cmet.2008.01.008
   PubMed Web of Science ®Google Scholar
• Azar R, Lasfargues C, Bousquet C, Pyronnet S. Contribution of HIF-1alpha in 4E-BP1 gene expression. Mol Cancer Res 2013; 11:54-61; PMID:23175522; http://dx.doi.org/10.1158/1541-7786.MCR-12-0095
   PubMed Web of Science ®Google Scholar
• Musti AM, Treier M, Bohmann D. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 1997; 275:400-2; PMID:8994040; http://dx.doi.org/10.1126/science.275.5298.400
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Poddar R, Deb I, Paul S. Dephosphorylation of specific sites in the kinase-specificity sequence domain leads to ubiquitin-mediated degradation of the tyrosine phosphatase STEP. Biochem J 2011; 440:115-25; PMID:21777200; http://dx.doi.org/10.1042/BJ20110240
   PubMed Web of Science ®Google Scholar
• Chang L, Zhou B, Hu S, Guo R, Liu X, Jones SN, Yen Y. ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage. Proc Natl Acad Sci U S A 2008; 105:18519-24; PMID:19015526; http://dx.doi.org/10.1073/pnas.0803313105
   PubMed Web of Science ®Google Scholar
• La P, Yang G, Dennery PA. Mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation stabilizes ISCU protein: implications for iron metabolism. J Biol Chem 2013; 288:12901-9; PMID:23508953; http://dx.doi.org/10.1074/jbc.M112.424499
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim HS, Lee SJ, Kim KT. Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death. J Cell Sci 2007; 120:2259-71; PMID:17591690; http://dx.doi.org/10.1242/jcs.03468
   PubMed Web of Science ®Google Scholar
• Sherrill KW, Byrd MP, Van Eden ME, Lloyd RE. BCL-2 translation is mediated via internal ribosome entry during cell stress. J Biol Chem 2004; 279:29066-74; PMID:15123638; http://dx.doi.org/10.1074/jbc.M402727200
   PubMed Web of Science ®Google Scholar
• Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, Brugge JS. Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells. Cancer Cell 2012; 21:227-39; PMID:22340595; http://dx.doi.org/10.1016/j.ccr.2011.12.024
   PubMed Web of Science ®Google Scholar
• Yu L, Shang ZF, Wang J, Wang H, Huang F, Zhang Z, Wang Y, Zhou J, Li S. PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability. Oncotarget 2015; 6:20356-69; PMID:26011939; http://dx.doi.org/10.18632/oncotarget.3931
   PubMed Web of Science ®Google Scholar